国药控股(01099) - 2024 Q1 - 季度业绩

Financial Performance - For the three months ended March 31, 2024, the total operating revenue was RMB 147.27 billion, an increase from RMB 145.52 billion for the same period in 2023, representing a growth of 1.2%[4] - The total operating costs for the same period were RMB 143.49 billion, up from RMB 141.41 billion, indicating an increase of 1.5%[4] - The net profit for the three months ended March 31, 2024, was RMB 2.40 billion, a decrease from RMB 2.81 billion in the previous year, reflecting a decline of 14.6%[4] - The company reported a decrease in the earnings attributable to shareholders, which was RMB 1.42 billion, down from RMB 1.59 billion, a decline of 10.6%[4] - Basic and diluted earnings per share for the three months ended March 31, 2024, were both RMB 0.46, down from RMB 0.51 in the same period of 2023, indicating a decrease of about 9.8%[5] - The total comprehensive income for the three months ended March 31, 2024, was RMB 2,393,149,541.07, a decrease from RMB 2,811,576,071.07 for the same period in 2023, representing a decline of approximately 14.9%[5] - Net profit for the three months ended March 31, 2024, was RMB 48,414,009.21, a decrease of 30.4% from RMB 69,617,785.98 in the prior year[10] - The total comprehensive income for the three months ended March 31, 2024, was RMB 48,732,165.54, down from RMB 69,203,467.71 in the prior year[11] Assets and Liabilities - The total assets as of March 31, 2024, amounted to RMB 413.07 billion, compared to RMB 383.24 billion as of December 31, 2023, marking an increase of 7.8%[3] - The total liabilities increased to RMB 290.20 billion as of March 31, 2024, from RMB 262.72 billion at the end of 2023, representing a rise of 10.5%[3] - Total assets as of March 31, 2024, were RMB 85,786,622,602.13, a decrease from RMB 102,630,062,151.69 as of December 31, 2023, indicating a decline of approximately 16.4%[8] - Total liabilities as of March 31, 2024, were RMB 52,243,829,715.17, down from RMB 69,136,001,430.27 as of December 31, 2023, reflecting a decrease of about 24.4%[9] - The company's total equity as of March 31, 2024, was RMB 33,542,792,886.96, slightly up from RMB 33,494,060,721.42 as of December 31, 2023, indicating a marginal increase of approximately 0.1%[9] Cash Flow - The cash and cash equivalents decreased to RMB 48.91 billion from RMB 74.82 billion, a decline of 34.6%[2] - Cash inflows from operating activities for the three months ended March 31, 2024, totaled RMB 119,516,955,411.13, compared to RMB 115,589,210,738.13 in 2023, reflecting an increase of approximately 3.8%[6] - The net cash outflow from operating activities was RMB 47,481,156,603.55 for the three months ended March 31, 2024, compared to RMB 40,693,448,172.89 in 2023, indicating a worsening of about 16.5%[6] - The net cash flow from investing activities was RMB 256,120,194.80 for the three months ended March 31, 2024, down from RMB 416,013,868.85 in 2023, representing a decline of approximately 38.4%[6] - Cash and cash equivalents at the end of March 31, 2024, were RMB 38,738,607,639.12, compared to RMB 36,527,789,116.72 at the end of March 31, 2023, showing an increase of about 6.0%[7] - The company reported cash inflows from financing activities of RMB 41,217,488,036.01 for the three months ended March 31, 2024, compared to RMB 43,913,421,118.35 in 2023, representing a decrease of about 6.1%[7] - Cash flow from operating activities showed a net outflow of RMB 1,912,528,692.92, compared to a net outflow of RMB 1,700,662,975.41 for the same period last year[12] - Cash flow from investing activities generated a net inflow of RMB 407,324,780.59, up from RMB 227,667,455.50 in the previous year[12] - Cash flow from financing activities resulted in a net outflow of RMB 17,134,426,936.48, compared to a net outflow of RMB 14,227,675,204.86 in the same period last year[13] Research and Development - Research and development expenses for the quarter were RMB 71.13 million, down from RMB 95.96 million, indicating a decrease of 25.5%[4] - The company has indicated plans for market expansion and new product development, although specific figures were not disclosed in the report[4] - The company’s investment income for the three months ended March 31, 2024, was RMB 53,504,018.73, compared to RMB 48,261,251.96 in the previous year, indicating a growth of 10.5%[10] - The company’s total assets decreased slightly, reflecting ongoing strategic adjustments in response to market conditions[10]